Author: admin

The partnership combines Nord Security’s secure access and credential management solutions with the CrowdStrike Falcon platform, delivering enterprise-grade protection that’s simple, accessible, and built for every business

AUSTIN, Texas – January 12, 2026 – CrowdStrike (NASDAQ: CRWD) and Nord Security today announced a strategic partnership to redefine SMB cybersecurity. The collaboration combines CrowdStrike’s AI-native Falcon® platform with Nord Security’s secure access and credential management solutions to deliver enterprise-grade protection that’s simple, accessible, and built for every business. 

Challenged by limited budgets and cyber security expertise, CrowdStrike’s State of SMB Cybersecurity Survey shows just 36% of small and midsize businesses are investing in new tools, and only 11% have adopted AI-powered defenses. At the same time, adversaries are increasingly targeting smaller organizations with enterprise-level attacks. This partnership directly addresses that gap, seamlessly giving SMBs access to the AI-powered protection, intelligence, and speed trusted by the world’s largest enterprises.

The partnership introduces two key innovations:

• Simplified e-commerce access: Nord Security will offer Falcon® Go, CrowdStrike’s AI-powered solution purpose-built for SMBs, and Falcon® Enterprise directly through NordLayer, a toggle-ready network security platform for business, pairing the power of the Falcon platform with NordLayer’s secure access to make enterprise-grade protection easy to buy and deploy. 
• Expanded MSP offerings through Pax8: CrowdStrike, Nord Security, and Pax8 will launch an add-on for Falcon® Next-Gen SIEM that combines speed, detection and accuracy of the Falcon platform with Nord Security’s secure access and network solutions, including 90 days of free access for qualifying customers.

“This partnership transforms how SMBs secure their business,” said Daniel Bernard, Chief Business Officer at CrowdStrike. “Together with Nord Security, we’re redefining cybersecurity for SMBs – combining the power of the Falcon platform with Nord Security’s SMB go-to-market prowess and secure access technology to deliver enterprise-grade protection that’s fast to deploy, simple to manage, and built to stop breaches.”

“Every growing business faces the same challenge: their attack surface is expanding faster than their ability to secure it,” said Mantas Ulozas, Chief Business Development Officer at B2B Commercial at Nord Security. “By combining our secure access and credential management solutions with CrowdStrike’s Falcon platform, we’re removing barriers of cost and complexity that have long limited SMBs’ access to enterprise-grade protection – giving them the visibility and confidence to defend against modern threats.”

For more information on the CrowdStrike-Nord Security partnership, visit here. 

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | X | LinkedIn | Instagram

Start a free trial today: https://www.crowdstrike.com/trial

© 2026 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

About Nord Security 

Nord Security is home to advanced cybersecurity solutions that share the Nord brand and values, including the world’s most advanced VPN service NordVPN, the next-generation password manager NordPass, the file encryption tool NordLocker, threat exposure management platform NordStellar, the toggle-ready network security platform for business NordLayer, an all-around identity theft protection service NordProtect, and Saily, an eSIM service. Established in 2012, Nord Security’s products are now acknowledged by the most influential tech sites and IT security specialists. More information: nordsecurity.com.

Press Contacts

Affordability, Agreements, and Action by Congress

Inu Manak is senior fellow for trade policy.

Despite the flurry of trade policy activity in 2025, President Donald Trump’s on-again, off-again tariff threats left the trade landscape largely intact. Tariffs are not nearly as high as anticipated, and firms took proactive measures to massively front-load the economy, delaying some tariff impacts. The year ahead is likely to be another roller coaster, but there are three trends in trade to keep a close eye on: the erosion of trade agreements, the effects of tariffs on affordability, and the potential limits of executive power in trade.

The United States is charting a new course on trade, but it is casting aside fundamental rules that have underpinned the global trading system in the process. That is pushing some of its closest allies away and could further fragment trade rules. The Trump administration has signed a handful of new trade deals and is likely to increase pressure on trading partners next year to make those deals deliver (or walk away from them if they do not). Closer to home, if Trump rips up the deal with Canada and Mexico that he negotiated in his first term, it will send shock waves throughout the U.S. economy.

That said, Trump was willing to test the limits of what markets would accept on tariffs this year; the effects of tariffs on affordability could continue to nag at him. The administration has exempted a range of household goods from tariffs, including bananas, beef, and coffee. If everyday items feel unaffordable, the administration could be pushed to respond with additional tariff relief.

Throughout U.S. history, every major tariff increase was legislated by Congress. Today, Congress has virtually no role. This is a precarious state of affairs, because it means that trade policy is now beholden to whoever holds the White House—and in this case, trade policy is being made by one person. With the Supreme Court set to rule on Trump’s use of emergency tariffs early this year, we will soon find out if there are any limits to the president’s trade powers.

Following the Money From Oil to Tech

Edward Alden is senior fellow at CFR, specializing in U.S. economic competitiveness, trade, and immigration policy.

Here is a rule for anticipating U.S. trade actions in 2026: follow the money. Despite promising tariff protections to revitalize American manufacturing, the Trump administration has selectively spared the wealthiest industries in the United States, from big tech to big oil.

Tech companies avoided the worst tariffs—semiconductors and smart phones were exempted—and even benefited as the administration eased export controls on China and knocked down Canada’s digital services tax. Europe will be the main target in 2026: the Trump administration wants a rollback of the European Union’s Digital Services Act and artificial intelligence regulations.

Conventional energy has also remained largely tariff-free, and new trade deals have included purchase commitments for U.S. natural gas and oil. More is likely, especially if Venezuelan oil is reopened to U.S. producers.

None of that bodes well for the biggest trade negotiation of 2026: the review of the United States-Mexico-Canada Agreement. The sectors at stake, especially autos and agriculture, have been the most harmed by the Trump actions to date. This year could be the death knell for three decades of free trade in North America.

Will Trade Policies Drop Drug Prices?

Thomas Bollyky is senior fellow for international economics, law, and development and director of the Global Health Program. Elena Every is research associate for Global Health, Economics, and Development. Chloe Searchinger is former research associate for Global Health, Economics, and Development.

In 2025, President Trump broke new ground by using trade tools in an effort to lower prescription drug prices at home, raise them abroad, and return drug manufacturing to the United States.

The tactic resulted in deals with foreign governments and pledges from drug manufacturers and alike, but the details and text of most of those commitments have not been released. The agreements with manufacturers are voluntary.

In 2026, we will be watching whether those trade deals generate real returns by lowering the sky-high costs that Americans pay for medicines and by reversing the U.S. pharmaceutical trade deficit, which has grown 9 percent annually over the last two decades—hitting record highs in 2025.

It may take a while. In exchange for a three-year reprieve from U.S. tariffs, fourteen drugmakers agreed to lower their Medicaid drug prices, launch future drugs at prices comparable to those in other countries, and invest over $480 billion in U.S. manufacturing. Yet, our analysis of earning statements of companies that produce specialized pharmaceutical manufacturing equipment suggests that those drugmakers have not begun acquiring the means yet to launch new production facilities in the United States.

In December, the United Kingdom agreed in principle to raise by 25 percent its cost-effectiveness threshold for medicines procurement that the UK’s National Health Service uses, although it is unclear whether that will result in the UK spending more and U.S. patients paying less for prescription drugs. The UK government reported that the cost allocations for the change had already been made earlier in 2025 and would not affect “frontline services.”

Is the United States Still Committed to Slowing China’s AI Progress? 

Chris McGuire is senior fellow for China and emerging technologies.

The United States’ approach to export controls on technology to China in 2026 could dictate whether the United States maintains its lead over China in artificial intelligence (AI) or whether China approaches parity.

Until 2025, export controls were the most important and most heavily used policy tool for slowing China’s technological progress in advanced technologies, particularly chip-making and AI. China has achieved real progress in those areas, but substantially less than if U.S. export controls had not been in place. Restrictions on the export of semiconductor manufacturing equipment (SME) have caused China’s advanced chip-making capabilities to significantly lag those of U.S. allies and partners in both quantity and quality, and restrictions on the export of AI chips have caused China’s AI models to lag U.S. models by at least seven months. Those controls have been imperfect, but effective.

The Trump administration has not effected a single regulation tightening export controls on China, however. It has done nothing to tighten controls on SME exports, which were strengthened annually by the Biden administration, and has substantially loosened restrictions on AI chip exports to China. Meanwhile, China’s circumvention efforts grow by the day.

If the U.S. export control regime on advanced technologies is not actively maintained, it will atrophy. That would risk allowing China to catch up at the worst possible moment: just as those advanced technologies are emerging as major drivers of U.S. economic growth and military modernization. 

Shares in banks and credit card firms have fallen after US President Donald Trump called for credit card costs to be capped.

On Friday, Trump wrote on Truth Social that interest rates on cards should be limited to 10% for one year from 20 January. He did not specify how such a cap might be introduced or whether such a move would be legally enforceable.

UK bank Barclays, which has a sizeable US card business, saw its shares fall 3.5%, while US firms such as American Express, Visa and Mastercard were also lower in early trading.

US banking associations say capping rates will make it harder for people to access credit and be “devastating” for millions of families and small businesses.

The average interest rate for credit cards in the US is roughly 20%.

In his statement on social media, Trump called for limiting it to 10%, reviving an idea he had put forward during his 2024 presidential campaign.

“Effective January 20, 2026, I, as President of the United States, am calling for a one year cap on Credit Card Interest Rates of 10%,” he wrote. “Please be informed that we will no longer let the American Public be ‘ripped off’ by Credit Card Companies.”

On Sunday, speaking to reporters on Air Force One, Trump said credit card companies would be “in violation of the law” if they did not comply with his demands.

American Express’s share price fell by 4% while Visa and Mastercard’s stock dropped more than 2%. Other US lenders including JPMorgan Chase and Bank of America also saw their shares open more than 1% lower.

Forcing companies to lower their lending rates rate would “upend the basic economics of the industry,” said Matt Britzman, senior equity analyst at Hargreaves Lansdown.

“Most banks would respond by cutting credit limits, closing riskier accounts, and scaling back rewards programmes, because they simply couldn’t cover losses at that price point.”

Nearly half of US households in 2022 carried credit card debt, according to the most recent survey of consumer finances by the Federal Reserve.

It found that those with a balance owed more than $6,000 (£4,454) on average – which, with interest rates around 20%, translated into roughly $100 in monthly charges.

The idea of capping credit card rates has won support from an unlikely coalition of lawmakers, uniting those on the far-left, such as Bernie Sanders, with populists that back Trump’s MAGA agenda.

But the path to bringing the proposal into force is unclear.

Similar plans have languished in Congress. The administration has also pushed to reduce the role of agencies that have regulated such issues in the past.

“Begging credit card companies to play nice is a joke,” Democrat Senator Elizabeth Warren said on X.

“I said a year ago if Trump was serious I’d work to pass a bill to cap rates. Since then, he’s done nothing but try to shut down the CFPB [Consumer Financial Protection Bureau]”.

Analysts said executive action by the White House would likely meet with legal challenge from the industry, which has had success in the past fighting regulation in the courts.

A joint statement from five US banking bodies said they shared the president’s goal “of helping Americans access more affordable credit”.

However, they added that the proposed cap would “reduce credit availability and be devastating for millions of American families and small businesses who rely on and value their credit cards, the very consumers this proposal intends to help”.

“If enacted, this cap would only drive consumers toward less regulated, more costly alternatives.”

Early last year, Sanders and fellow US senator Josh Hawley had introduced bipartisan legislation which aimed to cap interest rates on credit cards at 10% for five years, but it has yet to make it into law.

In April 2025, the Trump administration moved to throw out a regulation capping credit card late fees at $8. The rule had been brought in by President Joe Biden’s administration as part of a crackdown on “junk fees”.

News Summary:

• NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.
• The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.
• NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production.

J.P. Morgan Healthcare Conference—NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.

The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with NVIDIA’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.

Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from NVIDIA, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using NVIDIA BioNeMo™ as the critical platform.

“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”

“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” said David A. Ricks, chair and CEO of Lilly. “Combining our volumes of data and scientific knowledge with NVIDIA’s computational power and model-building expertise could reinvent drug discovery as we know it. By bringing together world-class talent in a startup environment, we’re creating the conditions for breakthroughs that neither company could achieve alone.”

Building a Continuous Learning System for Drug Discovery

The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly’s agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists. This scientist-in-the-loop framework aims to enable experiments, data generation and AI model development to continuously inform and improve one another.

Harnessing access to unprecedented compute for the industry, massive, high-quality data generation and NVIDIA BioNeMo as the platform to accelerate drug discovery, the teams will focus on building next-generation foundation and frontier models for biology and chemistry.

The new initiative expands on Lilly’s previously announced AI supercomputer and intends to harness investments in next-generation NVIDIA architectures, including NVIDIA Vera Rubin.

The AI factory Lilly announced last fall, which is the most powerful in the pharmaceutical industry, will train large biomedical foundation and frontier models for identifying, optimizing and validating new molecules with exceptional speed and accuracy. It will also support new and advanced applications in manufacturing, medical imaging and scientific AI agents.

Beyond drug discovery, NVIDIA and Lilly will explore opportunities to apply AI across clinical development, manufacturing and commercial operations to integrate multimodal models, agentic AI, robotics and digital twins.

The use of physical AI and robotics in the AI factory will also help Lilly enhance its capacity to manufacture high-demand medications and strengthen supply chain reliability. With NVIDIA Omniverse™ libraries and NVIDIA RTX PRO™ Servers, Lilly can create digital twins of its manufacturing lines to model, stress test and optimize entire supply chains before making physical changes in the real world.

Supporting Global Leadership in Biomedical Discovery

NVIDIA leads in open-source AI, empowering companies with the models, data and tools needed to develop real-world AI systems. In addition, the NVIDIA Inception program provides startups with access to technical mentorship, as well as NVIDIA software and compute.

Lilly TuneLab, an AI and machine learning platform, provides biotech companies with access to select Lilly models for drug discovery built on decades of Lilly’s proprietary data. TuneLab will include NVIDIA Clara™ open foundation models for life sciences as part of a future workflow offering.

The co-innovation lab will provide NVIDIA and Lilly’s startup ecosystems and researchers with deep expertise and scale of computing resources.

The lab’s work is expected to begin in South San Francisco early this year.